A prognostic nomogram integrating Epstein-Barr virus DNA and specific inflammatory indices for early recurrent or metastatic nasopharyngeal carcinoma after first-line nedaplatin-based therapy
Open Access
- 22 January 2026
- journal article
- research article
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Abstract
Purpose This study developed and validated a nomogram integrating specific inflammatory and Epstein-Barr virus (EBV) DNA quantification to predict overall survival (OS) in patients with nasopharyngeal carcinoma (NPC) who experienced recurrence or metastasis within ten years after completing first-line treatment with nedaplatin. Methods The nomogram was constructed utilizing data from a retrospective cohort of 120 patients treated at The People’s Hospital of Guangxi Zhuang Autonomous Region between January 2017 and December 2022. The predictive accuracy and clinical utility of the model were assessed through the concordance index (C-index), decision curve analysis (DCA), calibration plots, and time-dependent receiver operating characteristic (ROC) curves. Results Multivariate analysis revealed that an elevated albumin-to-globulin ratio (AGR) and lymphocyte-to-monocyte ratio (LMR) were significantly correlated with improved OS, whereas increased levels of alkaline phosphatase (ALP) and the presence of EBV DNA were associated with poorer prognostic outcomes. These four variables were integrated into a nomogram, which exhibited robust predictive accuracy, as evidenced by a C-index of 0.747 (95% CI, 0.689–0.805). This performance marked a substantial enhancement in discriminatory ability relative to the 8th edition UICC/AJCC staging system, which yielded a C-index of 0.566 (95% CI, 0.509–0.624). Additionally, the nomogram demonstrated satisfactory calibration, effectively stratified patients by risk (log-rank test, P < 0.001), and showed clinical applicability as confirmed through DCA. Conclusions This study successfully constructed a nomogram model for patients with NPC who experienced recurrence or metastasis within ten years following the completion of first-line treatment with nedaplatin. This model functions as an adjunct to the 8th edition UICC/AJCC staging system and provides significant support for clinical decision-making processes.Keywords
Funding Information
- Natural Science Foundation of Guangxi Zhuang Autonomous Region (2024GXNSFAA010066)
- National Natural Science Foundation of China (81960493)
This publication has 44 references indexed in Scilit:
- Transcriptomic profiling reveals mechanism, therapeutic potential, and prognostic value of cancer stemness characteristic in nasopharyngeal carcinomaFunctional & Integrative Genomics, 2025
- Predictive progression outcomes and risk stratification in patients with recurrent or metastatic nasopharyngeal carcinoma who received first-line immunochemotherapyClinical and Translational Oncology, 2023
- A predictive survival model for patients with stage IV oropharyngeal squamous cell carcinoma treated with chemoradiationEuropean Archives of Oto-Rhino-Laryngology, 2023
- Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?Current Treatment Options in Oncology, 2023
- A novel Epstein‐Barr virus subtype associated with nasopharyngeal carcinoma found in South ChinaCancer Communications, 2020
- Prognostic capacity of Systemic Inflammation Response Index (SIRI) in patients with head and neck squamous cell carcinomaHead & Neck, 2019
- The lymphocyte-to-monocyte ratio as a prognostic indicator in head and neck cancer: a systematic review and meta-analysisEuropean Archives of Oto-Rhino-Laryngology, 2018
- Neutrophil‐to‐lymphocyte ratio in head and neck cancer prognosis: A systematic review and meta‐analysisHead & Neck, 2018
- Concurrent chemoradiotherapy with nedaplatin plus paclitaxel or fluorouracil for locoregionally advanced nasopharyngeal carcinoma: Survival and toxicityHead & Neck, 2013
- Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinomaHead & Neck, 2012